ArticlePLoS neglected tropical diseases2026
Monitoring of Chlamydia trachomatis infection and antibodies in low-prevalence districts of Amhara, Ethiopia: Insights from a hyper-endemic trachoma region.
Article in PLoS neglected tropical diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTrachoma, an infectious eye disease caused by Chlamydia trachomatis (Ct), remains endemic in Ethiopia's Amhara region despite implementation of the Surgery, Antibiotic, Facial Cleanliness, and Environmental Improvement (SAFE) strategy since 2007. Once a formerly endemic district has reached the trachoma elimination threshold of a trachomatous inflammation-follicular (TF) prevalence of <5% among children ages 1-9 years and mass drug administration has been halted, there is concern that the prevalence could recrudesce back above 5% over time. Formerly endemic districts that are adjacent to still-endemic districts may be at greater risk of recrudescence. This study aimed to evaluate the inclusion of Ct infection and antibody testing to complement traditional clinical measures (TF) in Albuko, Bibugn, Debre Birhan Town, and Fagita Lekoma, four low-endemic districts at risk for recrudescence. METHODOLOGY: These four district-level surveys were conducted between March and May 2022. Children ages 1-9 years (n = 2,424) were assessed for TF by certified graders and provided dried blood spots (DBS) for serological analysis. Children ages 1-5 years (n = 1,588) also provided conjunctival swabs to test for Ct infection.
resultsThe TF prevalence in this age group was < 5% in all four districts. The antibody seroconversion rate (SCR) ranged from 0.1 per 100 children per year in Fagita Lekoma to 1.1 per 100 children per year in Debre Birhan Town, suggesting low transmission compared to proposed low-endemicity thresholds (SCR ≤ 1.6). Further, no positive Ct infection cases were detected across the four districts.
conclusionsThe data confirmed that despite being adjacent to trachoma-endemic districts, the four surveyed districts have maintained or achieved the elimination threshold. Additionally, the use of complementary indicators supported clinical evidence of very low disease transmission in these districts. This study highlights that including complementary indicators into surveys provides additional certainty for low-endemicity settings within a region still working towards trachoma elimination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.